Overview

Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Status:
Withdrawn
Trial end date:
2000-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients with metastatic or recurrent colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Chicago
Collaborator:
National Cancer Institute (NCI)
Treatments:
Irofulven